Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
NLR has previously been observed to correlate with complications in upper GI (1) and colorectal (2) surgery. The investigators sought to assess if a similar correlation can be identified in emergency general surgical patients and if the presence of suspected or confirmed COVID-19 may impact on this. Given the heterogeneity of emergency general surgery the investigators therefore plan to perform a retrospective review of patients having emergency laparotomies only at a single NHS site during COVID-19 pandemic. Assessment of outcomes and Neutrophil:lymphocyte ratio as a predictor of outcomes will be completed. Outcomes will be completed in line with the recent COVIDSurg study criteria (3). The primary outcome is 30-day mortality. Secondary outcomes are 7-day mortality, re-operation, length of stay, post-operative respiratory failure, post-operative ARDS (Acute Respiratory Distress Syndrome), post-operative sepsis and ITU (Intensive Therapy Unit)/HDU (High Dependency Unit) admission.
Description: Mortality
Measure: 30-day mortality Time: 30 daysDescription: Mortality
Measure: 7-day mortality Time: 7 daysDescription: Re-operation
Measure: Number of participants returning to theatre Time: 30 daysDescription: Inpatient stay during index admission
Measure: Length of stay Time: 30 daysDescription: Presence of respiratory failure in the post-operative period as defined in the clinical notes or discharge summaries
Measure: Post-operative respiratory failure Time: 30 daysDescription: ARDS diagnosed radiologically
Measure: Post-operative ARDS Time: 30 daysDescription: Presence of sepsis in the post-operative period as defined in the clinical notes or discharge summaries
Measure: Post-operative sepsis Time: 30 daysDescription: ITU/HDU admission post-operatively
Measure: ITU/HDU admission Time: 30 daysDescription: Other documented post-operative complications
Measure: Other complications Time: 30 daysDescription: Neutrophil:Lymphocyte Ratio will be recorded daily in the peri-operative period
Measure: Peri-operative NLR Time: First 3 post-operative daysDescription: Absolute platelet counts recorded daily in the peri-operative period
Measure: Post-operative platelet counts Time: First 3 post-operative daysDescription: Defined as the presence of increased PT (prothrombin time) OR APTT (activated partial thromboplastin time) OR TT (thrombin time) OR fibrinogen above 1.5X the upper limit of normal. Coagulation will either be defined as normal or abnormal for each patient if one or more of these derangement are identified.
Measure: Post-operative coagulopathy Time: First 3 post-operative daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports